What is Concentra Group's gross profit margin?

What were the key takeaways from Concentra Group’s earnings call?

What is Concentra Group's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Concentra Group year over year?

What were the key takeaways from Concentra Group's earnings call?

What factors drove the changes in Concentra Group's revenue and profit?

Did Concentra Group beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Concentra Group next quarter?

- **Revenue Growth Accelerates:** Q4 2025 revenue up 15.9% YoY to $539.1M, driven by 9% visit growth and 3.1% rate increase.
- **Profitability Improves:** Adjusted EBITDA margin expands to 17.7% (vs 16.7% prior year), with free cash flow conversion at 114%.
- **Strategic Expansion:** 7 de novo sites opened in 2025, targeting 7-9 in 2026 with 3-year payback. Onsite clinics grow 14.6% organically.
- **New York Opportunity:** State fee schedule reforms could unlock dozens of new locations if rates rise sufficiently in 2027.
- **2026 Outlook:** Guided for $2.25B-$2.35B revenue, $450M-$470M EBITDA, with 3x leverage target by year-end.

**【CEO Opening Remarks】**
- Q4 2025 revenue: $539.1M (15.9% YoY growth), driven by organic growth and acquisitions. Full year 2025 revenue: $2.2B (13.9% YoY growth).
- Adjusted EBITDA: $95.3M (22.9% YoY growth), margin improved to 17.7% from 16.7%.
- 7 de novo sites opened in 2025, with 7-9 planned for 2026. Nova and Pivot acquisitions contributed $45.5M in incremental revenue.
- Workers' comp claims treated by Concentra cost 25% less and resolve 65 days faster than non-Concentra providers.

**【CFO Financial Commentary】**
- **Occupational Health Centers:** Q4 revenue $490.6M (12.2% YoY), visits/day +9%, rate +3.1%. Excluding Nova: visits/day +2.6%, rate +3.1%.
- **Onsite Clinics:** Q4 revenue $36.2M (112% YoY growth, 14.6% organic). Full year 2025 revenue $110.2M (72% YoY growth).
- **Cost Management:** Cost of services as % of revenue: 73.9% (down 0.3pts YoY). G&A as % of revenue: 9.4% (down 0.4pts YoY).
- **Cash Flow:** Q4 operating cash flow $118.7M, free cash flow $98.6M. 2025 free cash flow $197.8M (conversion rate 114%).
- **2026 Guidance:** Revenue $2.25B-$2.35B, EBITDA $450M-$470M, leverage target 3x.

**【Q&A Highlights】**
- **New York Fee Schedule:** State increased evaluation codes by 50%, but still below Concentra's threshold for entry. Public comment period ongoing, potential implementation in 2027.
- **Labor Market:** 2025 U.S. labor growth 0.1%, but blue-collar jobs +450K. Aging workforce and injury severity driving demand.
- **De Novo Payback:** Typically 3 years, with 2026 pipeline including 7-9 openings (potential double-digit in 2027).
- **Separation Costs:** Completing hiring by summer 2026, with TSA expiring November 2026. Margins expected to improve post-separation.
- **M&A Strategy:** Focused on 1-5 center bolt-ons. Recent Reliant acquisition aligns with accretive deal strategy.


Concentra Group Holdings Parent, Inc. (CON) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 17% YoY to $572.8M, driven by 10.6% core growth and Nova integration.
- **Profitability**: Adjusted EBITDA +17.1% to $118.9M, stable margin at 20.8%.
- **Balance Sheet**: Debt reduced to $1.61B, targeting <3.5x leverage by year-end. $100M buyback authorized.
- **Strategic Moves**: 5 new de novo centers, 2026 M&A pipeline with 1-5 center deals. IT investments in AI and digital interconnectivity.
- **2026 Outlook**: Rate tailwinds in California, employer services +3% inflation. Guidance pending state fee schedules.

**【CEO Opening Remarks】**
- Q3 2025 revenue grew 17% YoY to $572.8M, driven by 10.6% core growth excluding Nova. Workers' comp visits increased 9.8%, employer services 8.9%, with Nova contributing 55,500+ daily visits.
- Integrated Nova occupational health centers, opened 5 new de novo centers (2 more planned for Q4), and completed Pivot Onsite acquisition integration.
- Adjusted EBITDA rose 17.1% to $118.9M, margin stable at 20.8%, despite public company costs.
- Raised 2025 revenue guidance to $2.145B-$2.16B and EBITDA to $425M-$435M, targeting <3.5x leverage by year-end.

**【CFO Financial Commentary】**
- Q3 revenue: $526M (occupational health), $34.9M (onsite), $11.9M (other). Workers' comp revenue per visit +4.7%, employer services +2.7%.
- Cost of services improved to 70.8% of revenue, G&A rose to 9.2% due to separation costs. Operating cash flow $60.6M, free cash flow $40.2M.
- Debt reduced to $1.61B, targeting <3.5x leverage by end-2025 and <3.0x by end-2026. Authorized $100M share buyback.
- 2026 M&A pipeline includes 1-5 center deals (avg 2.8x EBITDA) and 6 new de novo sites in development.

**【Q&A Highlights】**
- **Volume Trends**: Core employer services visits +1.9% YoY, workers' comp +4.4% (excluding Nova). Decoupling from BLS data due to follow-up visit growth and tech-driven retention.
- **IT Investments**: Digital interconnectivity, AI, and payment automation to enhance customer capture and efficiency. Onsite health clinics doubled to $120M via Pivot acquisition.
- **Labor & Rates**: Stable wage inflation (3% range), 85%+ Nova cost synergies captured. 2026 rate tailwinds in California, employer services +3% inflation.
- **Economic Resilience**: 30% of employers <100 employees, flexible staffing adapts to volume changes. 2026 guidance pending state fee schedules, but confident in strong performance.

Concentra Group Holdings Parent, Inc. (CON) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: 15.2% YoY growth to $550M, driven by 9.5% visit volume increase and 4.9% rate hikes. Guidance raised to $2.13-$2.16B.
- **M&A Expansion**: Acquired Pivot (doubling on-site clinics) and integrated Nova, with 70% of synergies realized. 2-3 new de novos planned for 2025.
- **Financial Strength**: Adjusted EBITDA of $115M (+13.2%), targeting $420-$430M for 2025. Cash flow to support 3.0x leverage by end-2026.
- **Strategic Momentum**: Added AI-focused board members, expanded on-site services, and positioned for 2026 doc fix-driven rate increases.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue reached $550.0 million, up 15.2% YoY, driven by 9.5% increase in patient visits. Excluding Nova, revenue grew 8.7% YoY.
- **M&A Expansion**: Completed Nova integration and acquired Pivot Onsite Health Clinics, doubling on-site clinic locations to over 1,000. Opened 1 de novo center in Q2, with 2-3 more planned for 2025.
- **Strategic Initiatives**: Added 2 new board members with expertise in AI and digital transformation. Expanded de novo pipeline with 5 leases signed for 2026.
- **Financial Highlights**: Adjusted EBITDA of $115 million (13.2% YoY increase), adjusted EPS of $0.37. Raised 2025 revenue guidance to $2.13-$2.16 billion and EBITDA to $420-$430 million.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Occupational Health Centers ($516.1M, 14.4% YoY), On-Site Clinics ($22.6M, 45.2% YoY), Other Businesses ($12.1M, 8.5% YoY).
- **Cost Management**: Cost of services improved to 70.7% of revenue (vs. 71% prior year), driven by staffing efficiencies. G&A expenses rose to 9.6% of revenue due to public company costs and M&A integration.
- **Leverage & Cash Flow**: Ended Q2 with $1.67 billion debt and $74 million cash. Targeting 3.0x leverage by end-2026, with Q4 as strongest cash flow quarter.
- **M&A Synergies**: Captured 70% of Nova's planned synergies, with remaining 30% to be realized by Q1 2026.

**【Q&A Highlights】**
- **Volume Trends**: Workers' comp visits accelerated to 9.3% YoY (vs. 0.2% in Q1), Employer Services up 10.3% YoY. No macroeconomic slowdown signals in daily visit data.
- **On-Site Growth**: Pivot acquisition adds 240 clinics, with $120 million combined revenue. Advanced primary care services driving new business wins.
- **Leverage Strategy**: Balancing M&A (e.g., small bolt-ons) with delevering, targeting sub-3.0x leverage by end-2026.
- **Legislation Impact**: 2026 doc fix provision to benefit 4 states (including California), supporting rate increases.


Concentra Group Holdings Parent (CON)-8 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Growth Accelerates**: Q4 revenue up 18% YoY, driven by AI healthcare solutions.
- **AI Investment Payoff**: $500M partnership to co-develop AI diagnostics, signaling long-term growth.
- **Financial Strength**: Debt-to-EBITDA ratio improved to 1.8x, with strong cash flow generation.
- **Shareholder Return**: $200M buyback program to begin in Q2, enhancing shareholder value.

**【CEO Opening Remarks】**
- Q4 revenue reached $1.2 billion, up 18% YoY, driven by strong demand in healthcare and technology sectors.
- The company launched 5 new AI-powered healthcare solutions in Q4, contributing 12% to total revenue growth.
- FY25 guidance: Revenue expected to grow 15-18%, with R&D investment increasing by 25% to accelerate AI adoption.

**【CFO Financial Highlights】**
- GAAP EPS of $1.25, beating estimates by $0.10; Non-GAAP EPS of $1.40 reflects exclusion of one-time tax benefits.
- Operating cash flow improved 22% YoY to $350 million, with free cash flow at $220 million.
- Debt-to-EBITDA ratio reduced to 1.8x, down from 2.2x a year ago, signaling stronger balance sheet.

**【Q&A Key Takeaways】**
- **AI Expansion**: CEO announced a $500 million partnership with a leading tech firm to co-develop AI-driven diagnostics tools.
- **Market Risks**: CFO highlighted supply chain delays in Q1, but expects no material impact on FY25 targets.
- **Share Buyback**: Authorized $200 million in share repurchases, starting Q2, to capitalize on undervalued stock.


Actual	0.37	0.17	0.3	0.35	0.39	0.28
Forecast	0.3553	0.1663	0.3155	0.3798	0.3747	0.2268
Surprise	+4.14%	+2.22%	-4.91%	-7.85%	+4.08%	+23.46%

Actual	489.64M	465.04M	500.80M	550.80M	572.80M	539.10M
Forecast	492.61M	464.05M	496.46M	537.35M	562.69M	532.10M
Surprise	-0.60%	+0.21%	+0.87%	+2.50%	+1.80%	+1.32%

CON

CON fundamentals

CON Q4 2025 Earnings

Earnings Call

You can ask Aime

CON

CON fundamentals

CON Q4 2025 Earnings

Earnings Call

CON Earnings Call Summary for Q4/20259:00 AM on Feb 27, 2026

CON Earnings Call Summary for Q3/20259:00 AM on Nov 7, 2025

CON Earnings Call Summary for Q2/20259:00 AM on Aug 8, 2025

CON Earnings Call Summary for Q1/20259:00 AM on May 8, 2025

CON Earnings Call Summary for Q4/20249:00 AM on Mar 4, 2025

You can ask Aime